Nervosave Therapeutics discovers and develops therapies that slow, stop and reverse a broad range of demyelinating peripheral nerve diseases. Our first aim is to develop best in class Gene Therapy for CMT1A patients and beyond for all demyelinating CMT diseases. We develop robust discovery programs targeting both CMT diseases and acquired demyelinating peripheral neuropathies such as diabetic peripheral neuropathy and Guillain-Barré syndrome.